All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
During the 63rd ASH Annual Meeting and Exposition, the Lymphoma Hub was pleased to speak with Emmanuel Bachy, Hospices Civils de Lyon, Lyon, FR. We asked, How did you use propensity score matching to compare real-world results from axi-cel and tisa-cel?
How did you use propensity score matching to compare real-world results from axi-cel and tisa-cel?
Bachy begins by outlining differences observed between the two treatments and details the trial design. He highlights higher complete response rates and progression-free survival for axi-cell; however, there was no difference in overall survival and duration of response. Finally, he discusses toxicities and the importance of this data for real-world applications.
Medicare announces coverage of chimeric antigen receptor (CAR) T-cell therapy in the United States (US)
The Centers for Medicare and Medicaid Services (CMS) announced that Medicare will pay for CAR T therapies.
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox